Seiji Shimada

Kansai Medical University

Papers

1

Total Citations

2

H-Index

1

About

Dr. Seiji Shimada is a urologic oncologist whose research centers on advanced prostate cancer management, particularly rare and diagnostically challenging subtypes. His most cited work investigates neoadjuvant endocrine therapy for prostate ductal carcinoma presenting with large multiple cysts—a condition that mimics benign pathology and complicates surgical planning. In a landmark 2020 case study, Dr. Shimada demonstrated that preoperative hormonal therapy effectively reduced a 7×8 cm polycystic mass compressing the prostate, enabling successful robot-assisted radical prostatectomy in a 71-year-old patient with gross hematuria and urinary retention. This contribution is especially significant because ductal carcinomas are aggressive and often diagnosed late due to their atypical MRI appearance and normal-to-moderately elevated PSA levels (6.47 ng/ml in this case). By showing that neoadjuvant endocrine therapy can downstage such complex tumors, Dr. Shimada has provided a critical strategy for improving surgical outcomes in patients who might otherwise be deemed inoperable. His work bridges the gap between radiological interpretation and surgical oncology, offering a reproducible framework for managing these rare, high-risk lesions. Though early in his career, Dr. Shimada’s focused contributions are already shaping clinical decision-making for challenging prostate cancer presentations.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
[Efficacy of Neoadjuvant Endocrine Therapy for Prostate Ductal Carcinoma with Large Multiple Cysts Prior to Robot-Assisted Laparoscopic Radical Prostatectomy].
2 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Kansai Medical University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago